BDB 018
Alternative Names: BDB-018Latest Information Update: 06 Jun 2023
At a glance
- Originator Seven and Eight Biopharmaceuticals
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Jun 2023 Seven and Eight Biopharmaceuticals and Eikon Therapeutics enters into a licensing agreement to develop and commercialize TLR7/8 agonists Worldwide
- 22 Jun 2021 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT04840394)
- 22 Jun 2021 Phase-I clinical trials in Solid tumours (Monotherapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT04840394)